The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe

Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe

September 2, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Resunab for Systemic Sclerosis Receives FDA Fast-Track Status
Systemic sclerosis (scleroderma) affects mostly women in mid-life and is a rare, serious and chronic autoimmune disorder. There are no treatments approved by the FDA, and the disease confers significant morbidity and mortality.

You Might Also Like
  • FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • Biosimilar for Infliximab Launched in Europe
Also by this Author
  • Sequential Therapy May Reduce Hip Fracture Risk; Plus New Biosimilar Available in Canada

Resunab has received FDA fast-track development status for treating systemic sclerosis.1 It entered Phase 2 clinical trials, in a double-blind, randomized, placebo-controlled study, which began in June, to evaluate its safety, tolerability, pharmacokinetics and efficacy in 36 patients aged 18–70 years with active diffuse cutaneous systemic sclerosis.2

Resunab is a novel, synthetic, oral endocannabinoid drug, which mimics the pharmacological effects of cannabinoids. It specifically binds to CB2 receptors on immune cells and fibroblasts. Non-clinical studies have shown that when resunab binds to CB2 it activates the production of specialized pro-resolving lipid mediators (SPMs), which stimulate an endogenous cascade accountable for resolving fibrosis and inflammation. The outcome of this cascade restores chronically activated immune systems back to homeostasis, while halting fibrosis and without causing immunosuppression.

Use of Infliximab Biosimilars Continues to Expand Abroad
In July, the central purchasing agency for Assistance Publique-Hôpitaux de Paris (AP-HP) selected the biosimilar infliximab to treat the hospital group’s patients with rheumatoid arthritis, Crohn’s disease and psoriasis—after a 45% discount on Inflectra (biosimilar infliximab, Hospira) was offered by the manufacturer. The decision by the hospital group was made in an effort to reduce drug spending.3,4 The innovator product Remicade will continue to be used on patients who are already being treated with infliximab. However, all infliximab-naive patients will be started on Inflectra (biosimilar infliximab). Quality, effectiveness and medication safety continue to be priorities in treating patients and will be closely monitored in all treated patients.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Corbus Pharmaceuticals Holdings Inc. News release: Corbus Pharmaceuticals’ investigational drug resunab granted fast-track status by the U.S. FDA for the treatment of systemic sclerosis. 2015 Aug 19.
  2. U.S. National Institutes of Health. Study record detail: Safety, tolerability, efficacy and pharmacokinetics of JBT-101 in systemic sclerosis. 2015 Aug 25.
  3. Blamont M. Exclusive: Hospira wins French biosimilar drug tender at 45% discount. Reuters. 2015 July 3.
  4. Generics and Biosimilars Initiative. News release: Biosimilar infliximab offered to French hospitals at 45% discount. 2015 July 31.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: infliximab

You Might Also Like:
  • FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • Biosimilar for Infliximab Launched in Europe
  • Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.

Comments

  1. Debendro Singh says

    September 21, 2015 at 5:07 am

    I am interesting to read about the Scleroderma. My mother has been suffering from the scleroderma since one year. So, I have been searching for
    perfect medicine of scleroderma. I feel so excited that Resunab has been approved by FDA.

    Reply
    • Raja choudhry says

      April 5, 2018 at 9:45 am

      Hey i am raja from india ghaziabad i have also scleroderma i am also trying for resunab

      Reply
  2. Debendro Singh says

    September 21, 2015 at 5:14 am

    I’m from India. Is Resunab available in India? From where will I get ? Please give me the address. I want to purchase for my mother who has been laying on bed due to
    scleroderma disease.

    Reply
    • Keri Losavio says

      September 21, 2015 at 7:54 pm

      You’ll need to contact your doctor for that information or the company that makes it: http://www.corbuspharma.com/contact

      Reply
  3. Taibing Wei says

    April 17, 2017 at 12:54 am

    I‘m from china,a lovely girl’s father.My heart is broken cause my daughter get Dermatomyositis which will ruin her future. She is only 6 years old, so young and so beautiful.I love her so much. I really want to know how and when can i get the resunab. please help us.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.